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Abstract
Aims: To study visceral leishmaniasis (VL) trends in 
Malta.
Methods: Analysis of epidemiological and clinical trends, 
a veterinary questionnaire and questioning  a canine laboratory 
testing facility.
Results: A decline in VL in the past 25 years (1980-2005) 
was noted for both paediatric (p<0.001) and adult (p=0.002) 
populations. No seasonal variation in infection rates was found. 
Serological testing was reliable and a useful adjunct to bone 
marrow diagnosis. Treatment with sodium stibogluconate 
was highly effective and there were no permanent sequelae 
associated with disease or treatment. Vets are encountering less 
canine VL with no differences in localities 
Discussion: The decline in VL was paralleled by a 
decline in the stray canine reservoir population and by better 
management of canine infection in both sanctuaries and in 
domestic settings.
Introduction
Visceral Leishmaniasis (VL) is a chronic parasitic infection 
caused primarily by Leishmania donovani in the Old World, 
and by Leishmania amazonensis in the New World.1 It infects 
approximately 400,000 individuals annually worldwide, 
with a predilection towards early childhood.2 It is a chronic 
illness characterized by irregular fever, hepatosplenomegaly, 
pancytopenia and progressive weakness and emaciation, 
which can result in death if left untreated. VL is particularly 
important in the setting of coexistent and rising rates of Human 
Immunodeficiency Virus (HIV) infection and for example, in 
southern Europe 25-70% of adult VL cases are associated with 
coexistent HIV, and 1.5-9.5% of individuals with HIV suffer from 
newly acquired or reactivated VL.3-5 Paediatric cases have also 
been reported in which both organisms have been isolated.6
The Maltese Archipelago comprises the islands of Malta, 
Gozo, and Comino, and is situated in the center of the 
Mediterranean Sea, 93 km south of Sicily and 288 km north 
of North Africa. VL is endemic in the circum Mediterranean 
region, including Malta. 
As in most endemic areas, the vast majority of affected 
cases occur in the childhood population.6 Notification of human 
cases of leishmaniasis was made compulsory in Malta in 1946, 
making this country an ideal location for epidemiological studies 
of VL. Unfortunately, notification is not compulsory for canine 
infections.7,8 The diagnosis of VL was first made in Malta in 
1911,9 and the cutaneous form of leishmaniasis is also found.10 
The vector is the female sandfly Phlebotomus perniciosus and 
dogs continue to be the local reservoir for human Leishmania 
infection.11 Specific treatment for leishmaniasis was first 
instituted by Caronia of Catania in 1914, using a mixture of 
sodium antimony tartarate.12 Pentostam has been used for the 
treatment of leishmaniasis since the 1940s,13 and the current 
recommended dose of Pentostam is 20 mg/kg/day for 30 
consecutive days. In an earlier study, we noted a declining 
trend in paediatric cases of VL.14 In this study, we reviewed 
Lieshmaniasis trends in Malta for all ages, with special focus 
on the paediatric age group, and relate this decreasing trend 
to present prevalence rates of infection in dogs and current 
treatment practices among Maltese vets.
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Methods
Patients: All Maltese cases of VL notified between 
1980 and 2005 were identified from Malta Health Division 
notification registers. Paediatric patients were defined as those 
aged 14 years or under. Case notes of paediatric cases were 
retrospectively examined, and a form detailing presentation, 
diagnosis, treatment, and complications thereof was completed 
for each patient. Data was then entered into an Excel spreadsheet 
for processing. At least one non-Maltese paediatric patient 
contracted VL during a brief visit to Malta, and 2 patients were 
not included (stay <2 weeks in all cases).
Vets were sent a questionnaire in order to outline number 
of cases of canine VL encountered, by locality, and treatment of 
such cases. Data on canine Indirect Fluoescent Antibody Test 
(IFAT) testing was obtained from a local private laboratory for 
the period 2002-2005. 
Definitions
A case of VL was defined as a patient with classical clinical 
features of VL and a positive bone marrow or a positive IFAT for 
VL. IFAT for VL has been available in Malta since 1989, and this 
test became widely used in the paediatric age group from 1990.
A positive bone marrow aspirate was defined as a bone marrow 
sample that showed the intracellular amastigote forms LDB. 
IFAT was performed using Bio-Merieux substrate slides and 
Binding Site FITC conjugate. A strongly positive test was taken 
as one positive at a dilution of at least 1/180 (St Luke’s Pathology 
Laboratory definition in conjunction with test manufacturers). 
In an extremely small minority of patients who presented with 
a clinical picture of VL but had a negative bone marrow aspirate 
in the era prior to the availability of IFAT, treatment for VL was 
instituted empirically, and confirmation of VL was reinforced 
by response to treatment. Relapse was also defined as above. 
Cure was based on clinical criteria, and in more recent years, 
confirmed by a negative IFAT eight to 12 months after cessation 
of treatment. 
Population
Population totals and paediatric population totals for 
1980-2005 were obtained from official Maltese Government 
publications.15
Veterinary study: A questionnaire was sent to a local 
veterinary representative who contacted all of the known 
practicing vets in Malta with a questionnaire. Questions asked 
included whether electronic records were kept by vets, the 
approximate number of dogs treated for leishmania every year, 
whether the severity of the disease has changed, and whether the 
disease is more prevalent in dog sanctuaries than in pets.
Lab study: Only one lab locally offered canine leishmaniasis 
testing up to 2006 (HSE) and only this lab was therefore 
included.
Statistics
Seasonal variation was analysed using Edward’s method of 
cyclic variation.16 The quadratic equations of Fleiss were used 
to calculate 95% confidence intervals (CI) for sensitivity and 
Year Total cases Paediatric cases
980 9 8
98 18 11
982 4 3
98 4 3
984 7 5
985 4 1
98 8 5
98 6 4
988 16 8
989 14 7
990 15 5
99 13 6
992 10 3
99 2 2
994 3 3
995 2 0
99 3 3
99 3 2
998 6 2
999 8 4
2000 7 5
200 5 3
2002 0 0
200 3 2
2004 4 1
2005 4 1
Table 1: Annual number of human leishmaniasis cases
Figure 1: Rates of visceral leishmaniasis per 1,000,000 
population (thin lines: adults, thick lines: paediatrics)
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for population rates.17 Chi test for trends was used to analyse 
incidence over time. A p value of 0.05 or less was taken to 
represent a statistically significant result.
Results
Human VL
Epidemiology
The incidence of VL in Malta has decreased over the 25 
year period studied (1980-2005: Table 1 and Figure 1). This 
was significant for both the paediatric (p<0.001) and adult 
(p=0.002) populations. No seasonal variation in infection rates 
was found (p=0.7).
Investigations
Serology was positive in 21 cases and negative in one case 
of VL who had a positive bone marrow, an overall sensitivity of 
95.1% (95% CI: 87.2 to 98.4%). Bone marrow aspirate failed to 
show LDBs in only four of the 81 cases, a sensitivity of 94.7% 
(95% CI: 86.2 to 98.3%). All four had repeated bone marrow 
aspirates, which were negative, but the clinical picture was highly 
suggestive of VL in all four. Treatment of VL was instituted in 
two cases (year of presentation 1996) that had positive IFAT. 
In two other cases, treatment for VL was instituted without a 
positive bone marrow owing to the unavailability of a serological 
test (year of presentation 1980). All four responded to treatment 
(see below). In four other cases, an initial bone marrow aspirate 
was negative, with subsequent positive bone marrow aspirates. 
There was no significant difference between the sensitivity of the 
two tests (p = 1.0). The sensitivity of combined bone marrow 
aspiration and IFAT was 97.5% (95% CI: 90.5 to 99.6%). 
Treatment
In this study, treatment for VL in the paediatric age group 
with antimonials, a relatively inexpensive class of drugs, is safe 
and curative, with a low relapse rate and no permanent sequelae 
were associated with the disease or its treatment. 
Lab study
Data on the number of IFAT tests performed in dogs from 
2002 to 2005 show that positive tests for LV have not decreased 
New cases seen annually 20-30 cases (n=4) 1-9 cases (n=1)
Compared to 5 years ago 25-50% less (n=4) No change (n=1)
Compared to 10 years ago 50-75% less (n=2) Unable to compare (n=3)
Is the disease milder Yes (n=4) No (n=1)
Any locality differences No (n=5) Yes (n=0)
Are more infected dogs seen 
in sanctuaries No (n=3) Do not practice in sanctuaries (n=2)
Table 2: Results of veterinary questionnaire
in the last five years (Dr. Alex Aquilina, HSE Laboratories, 
personal communication). These statistics are however 
difficult to interpret as repeat tests on the same dogs cannot 
be identified. 
Vet study
Five vets answered the questionnaire. The general impression 
of vets practicing in Malta in response to a questionnaire was that 
they are encountering less canine VL than to five and ten years 
ago (Table 2). There were no significant differences in localities 
from where the infected dogs originated and vets who offered 
their services to dog sanctuaries did not report an increase in 
the incidence of the infection in dogs kept in sanctuaries. Dogs 
who presented with more than four symptoms were more likely 
to be put down as the cure rate in such dogs was poor.
Discussion
The incidence of VL in Malta has dramatically decreased 
over the 25-year period studied and indeed, in 1946, when 
human diseases became compulsorily notifiable on the islands, 
the leishmaniasis figures were 1264 visceral cases, 36 cutaneous 
cases and 5 unspecified.7,11
This decline is attributed to the suppression of stray dogs 
due the establishment of several dog sanctuaries around the 
island, and the putting down or treatment of infected dogs with 
lifelong allopurinol.18
Although there are no official statistics regarding dog 
ownership in Malta, the general impression is that the Maltese 
are very keen dog owners and this is reflected by the ease 
with which dog owners sell litters of puppies and the frequent 
newspaper adverts related to sale of puppies in the local 
press. 
The ultimate aim is prevention of VL, and the ideal way of 
achieving this is by the eventual development of an effective 
vaccine. This goal is particularly important in view of the 
emerging resistance to antimonial drugs in some parts of the 
world, and both of these should be the targets of future research 
efforts, along with compulsory veterinary notification of infected 
canines.
The main limitation of this study is the poor vet response 
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rate, but this is unlikely to significantly bias our results as due 
to the small geographical nature of the island, individuals travel 
to all parts of the country in order to treat their pets.
Conclusions
In Malta, we have found a falling incidence of VL. This 
decline is attributed to better disease control in canines due 
to owner awareness of the condition, and its suppression/
treatment, and widespread control measures for stray dogs. 
Current practice includes the putting down of dogs with more 
than 4 features of canine leishmaniasis, while 10 years ago, such 
dogs were consistently treated with very poor cure rates, thereby 
increasing the local leismaniasis reservoir. Moreover, long-term 
allopurinol therapy is now routine, with low relapse rates.
Serological testing for VL is as sensitive as bone marrow 
aspiration. Treatment for VL in the paediatric age group with 
Pentostam, a relatively inexpensive drug, is safe and effective. 
To date, there appears to be very little resistance to this drug in 
Malta, and all patients were cured, with no disease or treatment 
related permanent morbidity or mortality. More expensive 
drugs, such as liposomal amphotericin B, should be reserved 
for cases which are resistant to treatment or which relapse after 
treatment. 
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